Versacloz (Clozapine) Patent Expiration, LOE Window & CMS Spending
Versacloz (Clozapine) by Douglas America: FDA Orange Book LOE 2028-05-01, 8 AB generics, $2.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Douglas America |
| FDA Application & Pathway | N203479 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-05-01 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $2.1M |
| 2024 Medicare Part D Spend | $1.3M |
| 2024 Medicaid Spend | $705K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |